PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitute of Hematology & Blood Diseases Hospital, China
About this trial
Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently remain incurable. For indolent T/NK-cell lymphomas that are unresponsive to first-line treatment, there are few treatment options available and the prognosis is poor. This study is an open-label, prospective clinical trial aimed at evaluating the feasibility, efficacy, and safety of PI3K inhibitors in the treatment of relapsed/refractory indolent T/NK-cell lymphomas. Patients will be treated with Linperlisib or Duvelisib, with an expected overall response rate of 60% for PI3K inhibitor treatment.
Eligibility criteria
Qualifiers
None
Disqualifiers
Subjects who have previously used any PI3K inhibitors;
Clinical conditions of dysphagia, malabsorption, or other chronic gastrointestinal diseases that may interfere with compliance and/or absorption of the study drug;
Unable to discontinue medications that may prolong the QT interval (such as antiarrhythmic drugs) during the study period;
Active viral, bacterial, or fungal infections requiring treatment (e.g., pneumonia);
Trial design
Treatments tested in this trial
- PI3K inhibitor
Treatment groups
51 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov